Benefits
Highly selective bifidogenic prebiotic at low dose
iXOS® (XOS) preferentially feeds Bifidobacterium species — beneficial bacteria associated with immune function, metabolic health, and reduced gut inflammation — at doses as low as 1g/day. This selectivity for beneficial bacteria over pathogenic species, at a dose 5–10x lower than inulin or FOS, makes iXOS® the most formulator-friendly prebiotic for inclusion in capsules and functional foods.
Gut microbiome diversity and health
Multiple clinical studies confirm XOS supplementation significantly increases Bifidobacterium counts, improves microbiome diversity, reduces pathogenic bacteria ratios, and improves gut transit time. These microbiome improvements translate to better immune function, reduced systemic inflammation, improved metabolic markers, and enhanced short-chain fatty acid (SCFA) production.
Metabolic and immune health benefits
XOS fermentation by gut bacteria produces butyrate, propionate, and acetate — short-chain fatty acids (SCFAs) that feed colonocytes, regulate immune T-cell differentiation, and improve insulin sensitivity. Clinical studies link XOS supplementation to improved blood glucose, reduced LDL cholesterol, and enhanced mucosal immune defense.
Mechanism of action
Selective Bifidobacterium fermentation and SCFA production
XOS passes undigested to the colon where Bifidobacterium species — possessing specific beta-xylosidase enzymes — selectively ferment it as a preferred substrate. This selective fermentation increases Bifidobacterium abundance and produces butyrate (colonocyte fuel, anti-inflammatory, histone deacetylase inhibitor), propionate (hepatic gluconeogenesis inhibitor, satiety signal), and acetate — SCFAs with systemic metabolic and immune benefits.
Clinical trials
Randomized, double-blind, placebo-controlled trial of xylooligosaccharides (XOS, 1-2.8 g/day) effects on gut microbiome composition, Bifidobacterium counts, and metabolic markers in healthy adults. (Lecerf et al. 2012, Br J Nutr — or related early XOS RCTs)
Healthy adults.
XOS at 1 g/day significantly increased Bifidobacterium counts and improved microbiome diversity. Modest reductions in fasting blood glucose. Note: XOS is unusually low-dose for a prebiotic — most prebiotics (inulin, GOS) require 5-10+ g/day for similar effects. The low effective dose makes XOS practical for inclusion in functional foods without meaningful FODMAP load.